ZabBio, Inc.  Study Protocol  
ZB-06 ZB-06-01 
V
ersion No.: 4.0  Page 1 of 53  Version Date: 28 October 2021 
CONFIDENTIAL  P
rotocol Title An exploratory  Phase  1 mechanism -of-action study of  
ZB-06, a vaginal film containing HC4-N, an anti -sperm 
monoclonal antibody 
Protocol Number  ZB-06-01 
US
 IND/EudraCT Number  PIND 147498 
D
evelopment Phase 1 
V
ersion  4.0 
D
ate October 28, 2021 
Spo
nsor  ZabBio , Inc.  
6160 Lusk Blvd., Suite 105 
San Diego, CA 92121  
I
MPORTANT:  CONFIDENTIAL  
This document contains proprietary and confidential information belonging to ZabBio, 
Inc.  Its contents may not be disclosed or used without the express written permission of 
ZabBio, Inc. 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 2 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 SPONSOR  PROTOCOL APPROVAL PAGE  
Name and title of the person(s) authorized to sign the protocol and the protocol amendment(s) 
for the ZabBio, Inc.  
 
 
 
 
   
Clinical   Date  
 
 
 
   
Regulatory  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Date  
 
 
 
 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 3 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 INVESTIGATOR AGREEMENT PAGE  
I agree:  
• To assume responsibility for the proper conduct of the study at this site and to conduct the 
study in compliance with this protocol, any future amendments and with any other study 
conduct procedures provided by ZabBio, Inc.  
• Not to implement any deviations from or changes to the protocol, including protocol 
amendments, without agreement from ZabBio, Inc. and prior review and written approval 
from the Institutional Review Board/Ethics Committee, except where necessary to 
eliminate an immediate hazard to the s ubjects or for administrative aspects of the study 
(where permitted by all applicable regulatory requirements).  
• That I am familiar with the appropriate use of the investigational drug, as described in this 
protocol and any other information provided by Zab Bio, Inc. including, but not limited to, 
the current Investigator’s Brochure provided by ZabBio, Inc.  
• To ensure that all persons assisting me with the study are adequately informed about the 
investigational drug and of their study- related duties and functi ons. 
• That I have been informed that certain regulatory authorities require ZabBio, Inc. to obtain 
and supply details about the investigator’s ownership interest in ZabBio, Inc. or the study 
drug, and more generally about his or her financial ties with ZabBio, Inc . ZabBio, Inc. will 
use and disclose this financial information solely for the purpose of complying with 
regulatory requirements.  
• To provide ZabBio, Inc. with such infor mation regarding ownership interest and financial 
ties (including those of my spouse and dependent children).  
• To provide a prompt update to this financial information if any relevant changes occur 
during the course of the study and for 1 year following com pletion of the study.  
• That ZabBio, Inc. may disclose information about such ownership interests and financial 
ties to the appropriate regulatory authorities. 
 
Eastern Virginia Medical School Clinical Research Center, Department of Obstetrics and 
Gynecology, 601 Colley Avenue, Norfolk, VA 23507 
Site Name and Location  
 
Andrea R Thurman MD, Professor of Obstetrics and Gynecology, EVMS  
Principal Investigator Name and Title  
Principal Investigator Signature                                               Date  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 4 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 TABLE OF CONTENTS  
SPONSOR PROTOCOL APPROVAL PAGE  .................................................................... 2 
INVESTIGATOR AGREEMENT PAGE  ............................................................................ 3 
TABLE OF CONTENTS  ....................................................................................................... 4 
CONTACT INFORMATION ................................................................................................ 8 
LIST OF ABBREVIATIONS  ................................................................................................ 9 
1 PROTOCOL SUMMARY ....................................................................................... 10 
2 INTRODUCTION..................................................................................................... 13 
2.1 Background  ........................................................................................................... 13 
2.1.1  Product description ......................................................................................... 13 
2.1.2  Study rational  ................................................................................................. 13 
2.1.3  Dose rationale  ................................................................................................. 14 
2.1.4  Nonclinical Studies: ....................................................................................... 15 
2.1.5  Clinical studies  ............................................................................................... 16 
2.1.6  Risks and benefits  .......................................................................................... 17 
3 STUDY OBJECTIVES AND MEASUREMENTS  ................................................ 18 
3.1 Study Objectives  ................................................................................................... 18 
3.1.1  Primary Objective:  ......................................................................................... 18 
3.1.2  Secondary Objective:  ..................................................................................... 18 
3.2 Study Endpoints  .................................................................................................... 18 
3.2.1  Primary endpoint:  ........................................................................................... 18 
3.2.2  Secondary endpoint:  ....................................................................................... 18 
3.2.3  Exploratory endpoints:  ................................................................................... 19 
4 INVESTIGATIONAL PLAN .................................................................................. 20 
4.1 Study Design  .......................................................................................................... 20 
4.2 Selection and Withdrawal of Subjects  ................................................................ 21 
4.2.1  Inclusion Criteria: ........................................................................................... 21 
4.2.2  Exclusion Criteria: ......................................................................................... 21 
4.2.3  Withdrawal of Subjects  .................................................................................. 22 
4.2.4  Replacement of Subjects  ................................................................................ 23 
4.3 Randomization and Blinding  ............................................................................... 23 
4.4 Prior and Concomitant Medications and illnesses  ............................................. 23 
5 STUDY DRUG MANAGEMENT  ........................................................................... 24 
5.1 Study Drug Formulation ...................................................................................... 24 
5.2 Study Drug Packaging and Labeling  .................................................................. 24 
5.3 Study Drug Handling and Storage  ...................................................................... 24 
5.4 Study Drug Administration ................................................................................. 25 
5.5 Study Drug Accountability Procedures  .............................................................. 25 
6 MEASUREMENTS AND EVALUATIONS  .......................................................... 26 
6.1 Efficacy Assessments  ............................................................................................ 26 
6.2 Safety Assessments ................................................................................................ 26 
6.3 Pharmacokinetic Assessments  ............................................................................. 26 
6.4 Other Assessments  ................................................................................................ 26 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 5 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 6.5 Study Visits and Procedures  ................................................................................ 26 
6.5.1  Visit 1 (Screening)  ......................................................................................... 27 
6.5.2  Visit 2 (Enrollment)  ....................................................................................... 28 
6.5.3  Visits 3, 6 and 9 (CMC Baseline [no product] Cycle, CMC ZB -06 Cycle, 
CMC post -product -use safety Cycle)  ............................................................. 29 
6.5.4  Visits 4, 7, 10 (PCT Baseline Cycle, PCT ZB -06 Cycle and post -product -
use safety cycle  .............................................................................................. 30 
6.5.5  Visits 5 and 8 (24 hours post PCT safety checks)  .......................................... 31 
6.6 Visit Windows  ....................................................................................................... 32 
7 DATA ANALYSIS METHODS ............................................................................... 33 
7.1 Data Management  ................................................................................................. 33 
7.2 Sample Size Determination  .................................................................................. 33 
7.3 Subject Populations for Analysis  ......................................................................... 33 
7.4 Interim Analysis  .................................................................................................... 33 
7.5 Statistical Analysis  ................................................................................................ 33 
7.5.1  Primary Endpoint:  .......................................................................................... 33 
7.5.2  Secondary Endpoint:  ...................................................................................... 34 
7.5.3  Exploratory Endpoints:  .................................................................................. 34 
8 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  ............................... 36 
8.1 Definition of an AE  ............................................................................................... 36 
8.2 Definition of an SAE  ............................................................................................. 36 
8.3 Clinical Laboratory Abnormalities and Other Abnormal Assessments .......... 37 
8.4 Method, Frequency, and Time Period for Detecting AEs and SAEs  ............... 37 
8.5 Documenting AEs and SAEs  ................................................................................ 38 
8.6 Follow -Up of AEs and SAEs  ................................................................................ 38 
8.7 SAE Reporting  ...................................................................................................... 39 
8.8 Post-Study AEs and SAEs  .................................................................................... 40 
9 STUDY ADMINISTRATION ................................................................................. 41 
9.1 Safety monitoring  .................................................................................................. 41 
9.1.1  Protocol Safety Review Team (PSRT)  .......................................................... 41 
9.1.2  Clinical Data Safety Review  .......................................................................... 41 
9.2 Data Handling and Recordkeeping  ..................................................................... 41 
9.2.1  Study Data  ...................................................................................................... 41 
9.2.2  Source Documentation ................................................................................... 42 
9.3 Regulatory and Ethical Considerations  .............................................................. 42 
9.3.1  Regulatory Authority Approval and Study Conduct  ...................................... 42 
9.3.2  Institutional Review Board/Independent Ethics Committee Approval  .......... 42 
9.3.3  Subject Informed Consent  .............................................................................. 43 
9.3.4  Investigator Reporting Requirements  ............................................................ 43 
9.4 Amendment of the Protocol  ................................................................................. 43 
9.5 Subject Data and Data Protection  ....................................................................... 44 
9.6 Study Personnel and Study Monitoring .............................................................. 44 
9.7 Quality Assurance  ................................................................................................. 45 
9.8 Study and Site Closure  ......................................................................................... 45 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 6 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 9.9 Records Retention  ................................................................................................. 46 
9.10  Informa tion Disclosure and Inventions  .............................................................. 46 
9.10.1  Ownership  ...................................................................................................... 46 
9.10.2  Confidentiality  ................................................................................................ 46 
9.10.3  Publication  ...................................................................................................... 46 
10 REFERENCES  .......................................................................................................... 48 
APPENDICES  ....................................................................................................................... 51 
 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 7 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 LIST OF TABLES  
Table 1: ZB -06 Product Composition Unit Dosage Form  ...................................................... 24 
 
LIST OF FIGURES  
Figure 1: ZB -06 Film Package Label ...................................................................................... 24 
 
LIST OF APPENDICES  
Appendix A. Schedule of Events  ............................................................................................ 52 
Appendix B. Table of actions according to PCT results  ......................................................... 53 
 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 8 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 CONTACT INFORMATION 
Role in Study  Name  Address and Telephone number  
Sponsor Project Physician  Thomas Moench,  MD 
 703 Stags Head Road  
Baltimore, MD 21286  
Phone : 443 -900-6696  
Medical Monitor  Thomas Moench, MD  
 703 Stags Head Road  
Baltimore, MD 21286  
Phone: 443- 900-6696  
Site Investigator Andrea Thurman , MD  Eastern Virginia Medical 
School /CONRAD  
601 Colley Ave.  
Norfolk, VA 23507  
Phone  757-446-8931  
Medical Safety Officer  David Archer, MD  Eastern Virginia Medical 
School /CONRAD  
601 Colley Ave.  
Norfolk, VA 23507  
Phone  757-446-7444  
24-Hour emergency contact  Miles Brennan , PhD  6160 Lusk Blvd., Suite 105  
San Diego, CA 92121  
Phone  405-250-9644  
EVMS Andrology laboratory  Estella Jones, PhD  EVMS, Clinical Research Center, 601 
Colley Ave., Norfolk, VA 23507  
Pharmacokinetics Laboratory   Deborah Anderson, PhD  Laboratory of Reproductive Health & 
Disease Prevention  
Boston University School of Medicine  
670 Albany Stre et 
Room 516  
Boston, MA  02118  
Safety/Screening Laboratory   LabCorp  
1447 York Court  
Burlington, NC 27215  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 9 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 LIST OF ABBREVIATIONS  
 
AE(s)  Adverse event(s)  
BV Bacterial Vaginosis  
CMC  Cervical mucus check  
CRF  Case Report Form  
CV Cervicovaginal  
CVL  Cervicovaginal Lavage  
GCP  Good Clinical Practice  
HIV  Human Immunodeficiency Virus  
HPF  High Powered Field  
ICF Informed Consent Form  
IRB Institutional Review Board  
IQR  Interquartile Range  
IUD Intra -Uterine Device  
mAb Monoclonal Antibody  
NAAT  Nucleic Acid Amplification Test  
NOAEL  No Observed Adverse Effect Level  
OPK  Ovulation Predictor Kit  
PCT  Post-Coital Test  
PBS Phosphate Buffered Saline  
PI Principal Investigator  
PK Pharmacokinetic  
PMS  Progressively Motile Sperm  
PSRT  Protocol Safety Review Team  
PVA  Polyvinyl Alcohol  
SAE  Serious Adverse Event  
STI Sexually Transmitted Infection  
TEAE  Treatment Emergent Adverse Events  
TOST  Two One -Sided T -Test Procedure  
VCF  Vaginal Contraceptive Film  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 10 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 1 PROTOCOL SUMMARY 
Protocol Title  An exploratory  Phase  1 mechanism -of-action study of  
ZB-06, a vaginal film containing HC4 -N, an anti -sperm 
monoclonal antibody  
Protocol Number  ZB-06-01 
Short Title  In vivo  anti-sperm activity of ZB-06 film 
Sample Size  Screen ~ 60 couples to complete  15 evaluable couples  
Population  Healthy women  18 – 50 years of age, who have normal 
menstrual cycles  and are not at risk of pregnancy due to prior 
surgical sterilization , and their male partners, with who m 
they are in a monogamous sexual relationship  
Centers  One: Eastern Virginia Medical School   
Study rationale  This study is intended to make a preliminary assessment of 
the potential contraceptive effectiveness  and safety  of ZB -06 
by observing its ability to r educe motile sperm access to the 
endocervix.  
Study Design  This is a n exploratory Phase 1, single center , open -label, 
crossover , mechanism of action study using a surrogate 
marker for contraceptive efficacy (the Standardized 
Postcoital Test, PCT) to asses s the contraceptive potential of 
the ZB -06 film.  
 
The study will enroll  up to 35 couples  to reach a total of 15 
fully  evaluable women who have completed the  baseline and 
the active- product post -coital visits .  
The expected duration of study participation for each 
participant will be approximately  three months , including the 
screening period.  
Schedule of 
Procedures/Evaluations  Visit 1: Screening  
Visit 2: Enrollment  
Visit 3: Cervical mucus check at midcycle  
Visit 4; Baseline (no product) postcoital visit  
Visit 5: 24 -hour follow -up  
Visit 6: C ervical mucus check at midcycle  
Visit 7: Postcoital visit after intercourse using ZB -06 film  
Visit 8: 24- hour follow -up 
Visit 9: Cervical mucus check at midcycle  
Visit 10: No -product postcoital visit 1 mo nth after ZB -06 
film use  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 11 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 Study Duration  Estimated total study duration , 18 months ; individual 
participation , three months  
Test product, dose, and 
mode of administration  
 ZB-06 film:  The ZB-06 film contains 20 mg of the H C4-N 
sperm -agglutinating antibody which  will be digitally inserted 
into the vagina by the participant 30 min before intercourse 
timed to midcycle, after documentation of sperm -receptive 
endocervical mucus i n the preceding mucus check visit.  
Reference therapy, dose, 
and mode of 
administration  Baseline PCT cycle , conducted without use of ZB-06 film 
 
Primary Objective  To assess the potential contraceptive activity of the ZB-06 
film using a surrogate assessment  for contraceptive efficacy : 
the degree to which progressively motile sperm can be 
excluded from  the endocervical mucus after intercourse 
preceded by a single admi nistration of the ZB -06 film, 
compared to the same evaluation performed after intercourse 
without film.  
Secondary Objectives  1. To assess the safety of a single dose of ZB-06 film 
preceding a single act of vaginal intercourse   
Exploratory Objective s 1. To determine  antisperm antibody concentrations and 
agglutination potency in vaginal fluids , endocervical 
mucus, and serum at baseline, and at 2- 3 and 24 hours 
after intercourse with and without product use, and after 
intercourse without product, 1 month after  product use  
2. To assess the effect of the film on cervicovaginal 
immune mediators  
Primary Endpoint  Number of progressively motile sperm in aspirated 
endocervical mucus  at Visit 7,  2-3 hours after sexual 
intercourse  using ZB -06 film. 
Secondary Endpoints  Incidence of Grade 2 or greater adverse events in the 
participant and /or her male partner in the interval between 
Visit 4 ( the baseline intercourse without product ) and Visit 6 , 
in comparison to the incidence of Grade 2 or greater adverse 
events in the interval between Visit 7 ( intercourse with 
product ) and Visit 9.  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 12 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 Exploratory Endpoint s 1. Concentrations of anti-sperm -antibody in vaginal fluid  
measured by ELISA  at baseline, at 2- 3 hours , and at 24 
hours after intercourse  with and without product us e, and 
at 1 month after product use  
2. Sperm agglutination titer in vaginal fluid measured by 
endpoint dilution at baseline, and at  2-3 hours and at 24 
hours after intercourse  with and without product use, and 
at 1 month after product use  
3. Concentrations of anti -sperm -antibody in endocervical 
mucus  measured by ELISA  at baseline, and at  2-3 hours 
and at  24 hours after intercourse  with and without 
product use, and at 1 month after  product use  
4. Sperm agglutination titer in endocervical mucus  by 
endpoint dilution measured at baseline, and at  2-3 hours 
and at  24 hours after intercourse  with and without 
product use, and at 1 month after product use  
5. Concentrations of anti -sperm antibodie s in serum  
measured by ELISA  at baseline, at  24 hours, and at 1 
month after exposure to ZB-06 film  
6. Sperm agglutination titer in serum  by endpoint dilution 
measured at baseline, and 24 hours and 1 month after 
exposure to ZB -06 film  
7. Concentrations of immune mediators in cervicovaginal 
lavage, measured via multiplex assays before and 24 
hours after intercourse with vs. without study product.  
8. Vaginal  pH at baseline and 24 hours after intercourse 
with vs. without study product. 
9. Nugent Score at Visit 6 baseline and 24 hours after 
intercourse with study product. 
 
 
 
 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 13 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 2 INTRODUCTION 
2.1 Background  
2.1.1 Product description 
ZB-06 is an intravaginal film containing 20 mg of the HC4 -N drug substance, an IgG1 
monoclonal antibody that binds to CD52g, a glycoform expressed on the surface of human 
sperm . Note that HC4 -N targets a unique glycan (CD52g) attached to a 12 amino acid pe ptide 
sequence designated CD52  (Diekman et al., 2000) . The CD52 peptide is abundant on the 
surface of human lymphocytes and other immune cells, but the molecule on immunocytes lacks 
the male -tract specific glycan CD52g. HC4- N does not bind to the CD52 pept ide, and thus 
does not bind immune cells , but binds  only to the male -tract specific glycan CD52g  expressed 
on sperm . When HC4 -N binds to sperm, it cross -links them causing them to agglutinate. The 
additional constituents of the film are a film -forming polymer (polyvinyl alcohol, PVA), 
maltitol, histidine, and polysorbate 20. The film is approximately 2” x 2”.     
2.1.2 Study rational  
The primary objective of the study is to determine whether the ZB-06 film’s novel mechanism 
of action, antibody mediated sperm aggl utination, shows promise in a surrogate -efficacy proof-
of-concept assessment.  
Two lines of in vivo  evidence suggest that human anti-sperm  antibodies may be effective. First, 
an agglutinating anti -sperm antibody was shown to be effective as a contraceptive in rabbits 
(Castle et al., 1997). And second, anti -sperm antibodies are observed in women suffering from 
immune infertility ( Ustay , 1967; Bronson 1999). Indeed, the HC4- N antibody was cloned from 
circulating B -cells of an infertile woman with high- titer anti- sperm antibodies in her blood and 
genital tract, and without other explanation for her infertility (Isojima S, 1989) . However, while 
in vitro  and in vivo data suggest that an anti -sperm  antibody might be efficacious, a 
demonstration of sperm inhibition in women  would be an essential demonstration to justify the 
continued development of anti -sperm  antibodies as  nonhormonal contracepti ves. This Phase 1 
exploratory proof -of-concept study of ZB -06 will provide the evidence on mechanism of action 
of this HCA, HC4 -N. 
The assessment that will be used to assess the mechanism of action and potential efficacy of 
the ZB -06 film  is termed the Standard ized Postcoital Test (PCT). This protocol, developed by 
CONRAD and Eastern Virginia Medical School in 1995, has become recognized as the 
appropriate early assessment of intravaginally- active contraceptive methods, including vaginal 
spermicides and cervical  barrier devices (Archer et al., 1995; Mauck et al., 1997; Mauck et al.,  
2004;  Burke et al., 2010; Mauck et al., 2017). We propose using the PCT to evaluate the highly  
novel mechanism of the ZB -06 film, namely sperm agglutination via antibody- mediated  
crosslinking.  The PCT is an appropriate test at this exploratory stage of product development 
because  a) multiple vaginally -active contraceptives that have been judged promising during 
PCT evaluation s have gone on to show contraceptive effectiveness in human contraceptive  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 14 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 trials (Shihata and Trussell, 1991; Mauck et al., 1996; Mauck et al., 1999; Barnhart et al., 
2007; Burke et al.,  2010; Schwartz et al., 2015; Barnhart et al., 2016), and b) the PCT  allows 
testing in women without putting them at risk of pregnancy because it is  conducted in women 
who have been surgically sterilized. The latter  consideration is particularly important because 
since the HC4 -N target (the CD52g antigen)  is not present on t he sperm of other species (other 
than chimpanzee), preceding animal  contraceptive testing of HC4 -N has not been possible. 
Moreover, the novelty of this approach (there  are no other contraceptives based on sperm -
agglutinating antibodies) makes it difficult to  determine its likely contraceptive efficacy. Thus, 
a mechanism -of-action study using the  PCT protocol in sterilized  women , is an appropriate 
early step in the assessment of the viability of this novel concept.  
Conducting this exploratory study in sterilized  women is also appropriate in light of  the 
potential risk of sperm -antibody immune complexes inducing an active anti -sperm  immune 
response that might prolong the contraceptive effect beyond the duration of the  HC4 -N 
antibody product in the female reproductive tract. We judge this to be an unlikely outcome but  
have nevertheless designed the study to investigate this possibility by including an additional 
study PCT  cycle one month after the PCT cycle using the ZB -06 film. We will thus be able to 
make a preliminary assessment of a  potential  actively induced anti-sperm antibody response 
to the use of the ZB -06 film  during semen exposure after  unprotected intercourse.  
Finally, this study will make preliminary assessments of safety and pharmacokinetics of the 
ZB-06 film.  
2.1.3 Dose rationale  
The amount of HC4- N mAb, 20 mg per ZB -06 DP film, matches the total mAb concentration 
for the similar MB66 film  studied previously, conta ining anti-viral antibodies intended for 
prevention of HIV and HSV . Three lines of evidence suggest that the dose of HN4 -N in ZB -
06, inserted intravaginally 30 minutes to 4 hours post ZB -06 insertion, will be sufficient to 
prevent the large majority of spe rm from reaching the upper region of the cervix post coitus : 
1. Concentration of HC4- N needed for sperm agglutination in vitro : The concentration of 
HC4 -N needed to agglutinate sperm within ~100 seconds is 40 μg/mL . The resting 
volume of intravaginal fluid has been estimated to be approximately 1 mL (Owen and 
Katz, 1999) , with coital increases due to sexual excitement and semen depo sition, 
typically  raising the total volume to between 3 and 10 mL. A 20 mg dose of HC4- N 
would be expected to result in an antibody concentration of ~ 2,000 ug/mL. 
2. Concentration of HC4- N needed for sperm agglutination in a surrogate sheep study:  As 
a preli minary test of in vi vo vaginal sperm agglutination in an animal model with 
similar vaginal dimensions to humans, 1 mL of HC4- N (333 ug/mL and 33 ug/mL ; n = 
3 for each group) in PBS, or PBS alone was instilled into the vaginas of sheep, with the 
investigato rs blinded as to the presence or absence and concentration of the antibody. 
Coital stirring was mimicked by stir ring with a vaginal dilator for 10 seconds. Five 
minutes after dosing, 1 mL of fresh, liquified, pooled human semen was instilled, and 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 15 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 an additi onal five thrusts with the vaginal dilator were performed. Two minutes after 
instillation of semen, vaginal fluid was aspirated and immediately assessed for the 
number of progressively motile sperm. Expressed as a percentage reduction in 
progressively moti le sperm from that observed in the PBS control, the reduction was 
100% after instillation of 333 ug/mL (333 ug total dose), and 44% after instillation of 
33 ug/mL (33 ug total dose).  
3. Monoclonal antibody concentration in vivo  from the MB66 clinical study: From the 
pharmacokinetic (PK) data from the MB66- 01 clinical trial (Politch et al., submitted) , 
the concentration of VRC01 at 1 and 4 hours after application of MB66 is ~500 
microgram/mL at the cervical os. As the amount of VRC01 is 10 mg/ MB66 film, and 
the amount of HC4- N in a ZB -06 film is 20 mg, the anticipated concentration of HC4-
N mAb is twice this , thus ~1 ,000 ug/mL.  
Dose selection summary: As the concentration of HC4- N needed for complete sperm 
agglutination is ~40 microgram/mL in vitro  and 33 -333 m icrogram/mL in the sheep model, we 
anticipate that the concentration predicted by the VRC01 PK data at 1 and 4 hr post application 
(~1,000 ug/mL at the cervical os) will be sufficient to agglutinate all or nearly all sperm  in the 
ejaculate.  The dose of 20 mg of HC4- N per film is near the maximal dose that can be 
formulated into a film of this size and composition. We have chosen to use this near maximum 
Mab dose in order to improve the probability of robust protection. We have a high expectation 
of safet y for these antibodies, which are fully human amino acid sequences with glycosylation 
patterns very similar to those of human antibodies. We believe such antibodies justify a 
strategy of choosing a dose near the practical limit in order to improve potency and duration 
of action.  
2.1.4 Nonclinical Studies :  
A brief summary of the nonclinical safety studies performed with ZB -06 is provided below. 
Additional details can be found in the Investigator’s Brochure for ZB -06. 
2.1.4.1 Tissue Cross Reactivity  
A tissue cross reactiv ity study was performed to determine the potential cross  reactivity of 
HC4 -N with cryosections from a full panel of normal human, non- human primate (cynomolgus 
monkey), and rat (Sprague -Dawley) tissues.  Epithelial cells in the human epididymis w ere 
selected as an  ancillary control  tissue  due to the reported expression of CD52g in this tissue 
element  (Johnston, et al., 2020; Norton, et al., 2002) . In order to detect binding, HC4 -N was 
applied to cryosections of  tissues at two concentrations (10 and 2 µg/mL).  
HC4 -N stained the membrane and cytoplasm of epithelial cells in human epididymis consistent 
with the reported expression of CD52g in this cell type. In addition, m embrane and cytoplasmic 
staining was observe d with HC4 -N in mesothelial cells in several tissues and ovarian surface 
epithelial cells in all three species, as well as in mononuclear cells in the rat spleen, although 
no literature was located describing CD52g expression by any of these cell types. HC 4-N 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 16 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 produced cytoplasmic reactivity in retinal cells in all species, mononuclear cells in humans, 
lymphocytes in humans, and epithelial cells in a few tissues in all species. The  reactivity in 
these cell types was restricted to the cytoplasmic compartment,  and monoclonal antibody 
binding to cytoplasmic sites in tissue cross -reactivity studies generally is considered of little to 
no toxicologic significance due to the limited ability of antibody drugs to access the 
cytoplasmic compartment in vivo (Hall, et a l., 2008; Leach, et al., 2010) . 
2.1.4.2 Rat toxicology test  
An in vivo  toxicology study was performed to evaluate the potential effects, identify target 
organs of toxicity, and to estimate the no observed adverse effect level (NOAEL) and the 
maximum tolerated dose  (MTD) of ZB -06 after 9 consecutive intravaginal administrations to 
adult, female Sprague Dawley rats followed by 14 days of recovery.  
All animals survived to the end of the study, and there were no test -article related body weight 
changes, clinical obser vations, clinical chemistry, urinalysis, gross necropsy, or histopathology 
findings that were considered to be toxicologically significant. Minimal, reversible changes in 
hematology were observed in the high- dose group compared with the control group, howe ver 
there were no correlating macroscopic and microscopic findings or irritation associated with 
ZB-06 treatment, therefore these changes were not considered to be adverse.  
Based on the absence of any irritation or  any toxicologically significant adverse e ffects in any 
of the parameters evaluated  following daily intravaginal administration of ZB -06 for 9 days to 
adult female rats , the NOAEL for ZB-06 was considered to be 5 mg/day.  A maximum tolerated 
dose could not be determined in the study. 
2.1.4.3 Rabbit vaginal irritation test 
A rabbit vaginal irritation  study was  performed  to evaluate the potential for vaginal irritation 
following intravaginal administration of  ZB-06. The study evaluated once daily intravaginal 
administration of suspensions of ZB -06 at 1, 4, and 16 mg/mL for 10 consecutive days to New 
Zealand White Rabbits.  Repeat administration of ZB -06 did not result in any meaningful 
effects on survival, detailed clinical obs ervations, body weight/body weight change, 
hematology, coagulation, clinical chemistry, macroscopic, or organ weight evaluations.  Test 
article -related microscopic findings were present in the vagina at ≥4 mg/mL but were not 
considered adverse due to their  lack of severity .  
Based on the absence of any adverse effects following once daily intravaginal administration 
of suspensions of ZB -06 to New Zealand White Rabbits at 1, 4, and 16 mg/mL for 10 
consecutive days, the NOAEL for ZB -06 was  considered to be >16 mg.  
2.1.5 Clinical studies  
There have been no human studies  of the HC4 -N drug substance or the ZB -06 film drug 
product. 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 17 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 2.1.6 Risks and benefits  
This is the first study of ZB -06 in humans, and therefor e its risks are not known.  The animal 
studies done to date do not raise significant concerns. Prior clinical experience with similar 
PVA- based vaginal films such as a marketed nonoxynol -9 based contraceptive film ( Vaginal 
Contraceptive Film, Apothecus Pharmaceutical Corporation), have side effects including 
vaginal irritation/inflammation, vaginal burning, vaginal discharge, and penile irritation for 
male sexual partners. Rare but serious side effects may include severe allergic reactions with 
rash, hives, and itching. There are no  expected benefits to study participants , other than the 
possible satisfaction of having aided in the evaluation of a novel contraceptive method. 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 18 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 3 STUDY OBJECTIVES AND MEASUREMENTS  
3.1 Study Objectives  
3.1.1 Primary Objective :  
To assess the potential contraceptive a ctivity of the ZB -06 film using a surrogate assessment  
for likely contraceptive efficacy  (the degree to which progressively motile sperm can be 
excluded from  the endocervical mucus ). 
3.1.2 Secondary Objective : 
To assess the safety of a single dose of ZB -06 film used with a single act of vaginal intercourse  
among female participants and their male partners.    
3.1.3    Exploratory Objective s:  
o To determine antisperm antibody concentrations and agglutination potency in vaginal 
fluids, endocervical mucus, and serum at baseline, and at 2 -3 and 24 hours after 
intercourse with and without product use, and 1 month after product use  
o To assess the effect of the film on cervicovaginal immune mediators   
3.2 Study Endpoints  
3.2.1 Primary endpoint :   
Number of progressively motile  sperm in aspirated endocervical mucus 2- 3 hours after sexual 
intercourse  using ZB -06.  
3.2.2 Secondary endpoint :  
Incidence of Grade 2 or greater adverse events in the participant and/or  her male partner in the 
interval between Visit 4 ( the baseline intercourse without product ) and Visit 6 , in comparison 
to the incidence of Grade 2 or greater adverse events in the interval between Visit 7 ( intercourse 
with product ) and Visit 9.        
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 19 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 3.2.3 Exploratory endpoints:    
1. Concentrations of anti -sperm -antibody in vaginal fluid, measured by ELISA  at 
baseline, at 2- 3 hours , and at 24 hours after intercourse  with and without product 
use, and at 1 month after product use  
2. Sperm agglutination titer in vaginal fluid measured by endpoint dilution at baseline, 
and at  2-3 hours and at 24 hours after intercourse  with and without product use, and 
at 1 month after product use  
3. Concentrations of anti -sperm -antibody in endocervical mucus , measured by ELISA  
at baseline, and at  2-3 hours and at  24 hours after intercourse  with and wit hout 
product use, and at 1 month after product use  
4. Sperm agglutination titer in endocervical mucus , by endpoint dilution measured at 
baseline, and at  2-3 hours and at  24 hours after intercourse  with and without product 
use, and at 1 month after product use  
5. Concentrations of anti -sperm antibodies  in serum , measured by ELISA  at baseline, 
at 24 hours, and at 1 month after exposure to ZB -06 film  
6. Sperm agglutination titer in serum  by endpoint dilution measured at baseline, and 
24 hours and 1 month after exposure to ZB -06 film 
7. Concentrations of immune mediators in cervicovaginal lavage , measured via 
multiplex assays before and 24 hours after intercourse with and  without study 
product.  
8. Vaginal  pH at baseline and 24 hours after intercourse with vs. without study 
product. 
9. Nugent Score at Visit 6 baseline and 24 hours after intercourse with study product. 
 
 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 20 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 4 INVESTIGATIONAL PLAN 
4.1 Study Design  
This is a Phase 1, single center, open label, non- randomized, crossover, mechanism of action  
study, using a surrogate marker for contraceptive efficacy (the Standardized Postcoital Test, 
PCT) to assess the mechanism of action and contraceptive potential of the ZB -06 film.  
The product to be tested is the ZB -06 vaginal film, containi ng 20 mg of the HC4 -N anti-sperm 
antibody. Participants will be women who are not at risk for pregnancy due to surgical 
sterilization , and their male sexual partners.  The individual evaluating the cervical mucus for 
midcycle characteristics and presence o f sperm will be blinded as to the treatment cycle.  Each 
participant will be seen in approximately ten visits, over a period of 3 - 6 months.    Volunteers 
will be consented at Visit 1 and undergo procedures to confirm they are eligible to continue in 
the study.  Each participant will undergo three PCT cycles.  The first PCT cycle will be a 
baseline cycle, done without the use of any product, in order to demonstrate the participant’s 
ability to undergo normal ovulatory events and to produce receptive, midcy cle cervical mucus.  
The male partner’s ability to produce motile sperm capable of penetrating the cervical mucus 
is also evaluated in this baseline cycle.  A product use PCT cycle will be carried out during the 
subsequent menstrual cycle using the ZB-06 film.  An additional PCT cycle without product 
will be carried out during the subsequent menstrual cycle.  Cycles may need to be repeated 
depending on the characteristics of the cervical mucus and the number of sperm found in the 
vaginal pool and endocervi cal specimens  (see Appendix B ). 
The primary endpoint will be an assessment of  the potential contraceptive activity of the ZB -
06 film using a surrogate assessment for contraceptive efficacy, i.e., observing the degree to 
which progressively motile sperm can be excluded from the endocervical mucus.   
At ovulation, the participant’s cervical mucus will be assessed by Insler scor ing.  Once 
adequate cervical mucus is documented to be present , the couple will have unprotected 
intercourse within approximately 24 hours of the cervical mucus check.  Two to three hours 
after intercourse, the participant ’s vaginal fluid and cervical mucus will be evaluated for the 
presence of sperm (motile, immotile).  The expectation is that at baseline, participants will 
have an aver age of greater than 5 motile sperm per high power field ( HPF), averaged over 9 
HPFs, and that with the use of the ZB -06 film, participants will on  average have at least a 10 -
fold reduction in motile sperm per HPF , averaged over 9 HPF s.   
The secondary  objective will be assessed at each visit, by querying participants regarding any 
treatment -emergent adverse events ( TEAEs ).  TEAEs from the male sexual partner will be 
assessed at each visit, per the female participant’s report or from the male directly.  The m ale 
partner will be interviewed for TEAEs by phone within 72 hours of intercourse with product. 
Safety will also be assessed by comparing the concentrations of cervicovaginal ( CV) mucosal 
cytokines and chemokines with and without ZB -06 film use.   
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 21 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 Finally,  an estimation of the in vivo  pharmacokinetics  of HC4 -N will be described in serum 
cervical mucus, and CV fluid.  Our expectation is that serum levels of ZB -06 will be very low 
to unquantifiable, while CV fluid levels will be high, supporting local activity of the product.   
A listing of all study procedures and sampling is provided in the Schedule of Events Table in 
Appendix A . 
4.2 Selection and Withdrawal of Subje cts 
4.2.1 Inclusion Criteria : 
• Age 18 -  50 years, inclusive  
• General good health, by volunteer history and per investigator judgment  
• History of regular menstrual cycles of 21 - 35 days (inclusive), by volunteer report  
• History of a normal PAP smear or ASCUS with ne gative HPV testing within the 
previous 12 months  
• Willing to abstain from intercourse and use of vaginal medications, lubricants, and 
other products  as required in the protocol  
• Willing to use non- spermicidal, lubricated condoms for any vaginal intercourse from 
the first day of each menstrual cycle until 72 hours before expected midcycle  
• In a mutually monogamous relationship with a male partner who:  
o Is at least 18 years old  
o Has no  known risk for sexually transmitted infections ( STIs ) 
o Is willing and able to comply with protocol requirements including sexual 
activity/ abstinence and condom use requirements  
o Can engage in vaginal intercourse with the participant, with and without 
condoms, as specified in protocol  
o Is not taking exogenous hormones (e.g. testosterone)  
• Protected from pregnancy by female surgical  sterilization   
• Vaginal and cervical anatomy that, in the opinion of the investigator, lends itself to 
easy genital tract sample collection  
• Willing to give voluntary consent, sign an informed consent form and comply with 
study procedures as required by the protocol  
 
4.2.2 Exclusion Criteria : 
• History of hysterectomy 
• Surgical sterility  or known history of infertility in male partner  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 22 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 • Sterility or known history of sperm dysfunction in male partner  
• Currently pregnant by urine pregnancy test at the enrollment visit, or within two 
calendar months from the last pregnancy outcome.  Note: If recently pregnant must 
have had at least two spontaneous menses since pregnancy outcome  
• Current use of any hormonal contraceptive or a copper or hormonal IUD, or use of 
Depo -Provera in the last 120 days  
• Currently breastfeeding or having breastfed an infant in the last two months, or 
planning to breastfeed during the course of the study 
• Significant gynecological abnormalities (including abnormal vaginal bleeding, 
excessive vaginal discharge, or vulvar/vaginal pain or irritation)  
• Current UTI, vaginal candidiasis, or  symptomatic bacterial vaginosis  
• History of sensitivity/allergy to ZB -06 film components , for either the volunteer or her 
male partner   
• In the last three months, either the volunteer or her male partner diagnosed with or 
treated for any STI or pelvic inflammatory disease , or either partne r with know n risk 
factors for sexually transmitted infections . Note: Women with a history of genital 
herpes or condylomata who have been asymptomatic for at least six months may be 
considered for eligibility  
• Positive test for Trichomonas vaginalis, Neisser ia gonorrhea, Chlamydia trachomatis , 
or HIV at the screening visit  
• Deep epithelial genital findings such as abrasions, ulcerations, and lacerations, or 
vesicles suspicious for a n STI  
• Known current drug or alcohol abuse which could impact study compliance  
• Participation in any other investigational trial within the last 30 days or planned 
participation in any other investigational trial during the study 
• History of gynecological procedures (including genital piercing) on the external 
genitalia, vagina or cerv ix within the last 14 days  
• Abnormal finding on laboratory or physical examination or a social or medical 
condition in either the volunteer or her male partner which, in the opinion of the 
investigator, would make participation in the study unsafe or would complicate 
interpretation of data  
 
4.2.3 Withdrawal of Subjects  
Participants who sign the informed consent and agree to participate in the study, but do not 
meet eligibility criteria prior to undergoing the initial cervical mucus check (Visit 2) will not 
continue in the study.  No electronic case report forms (eCRFs) will be completed for 
participants who do not undergo the cervical mucus check at Visit 2.  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 23 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 Once a participant undergoes Visit 2 procedures, she may be withdrawn from the study for the 
following reasons:  
• Inability to achieve adequate cervical mucus in two attempts at the baseline cycle  
• Inadequate sperm in endocervical aspirate during baseline testing, despite adequate 
mucus and presence of sperm in vaginal pool  
• Medical reasons, including diagnosis of a n STI (in the participant or her partner) or any 
intercurrent illness that would jeopardize the participant’s health or the interpretation 
of the results of the study  
• Failure to follow protocol requirements that is judged severe enough by the investigator 
to significantly affect study outcomes  
• Pregnancy  
• Any AE, laboratory abnormality, or intercurrent illness which, in the opinion of the 
investigator, indicates that continued participation in the study is not in the best interest 
of the subject  
• Personal reasons (participant request)  
• Discontinuation of entire study 
 
4.2.4 Replacement of Subjects  and or Repeat of Product Use Cycle  
Approximately 15 women will complete the study.  Participants who discontinue early may 
not re -enroll.  Participants who disc ontinue may be replaced  as needed to achieve the desired 
full 15 women completing both a baseline and a product PCT cycle .  Participants who have a 
failed product use cycle, due to factors such as but not limited to: erectile dysfunction, inability 
to ejaculate , illness,  etc., may repeat the product use cycle with a second dose of the 20 mg 
film, in a subsequent menstrual cycle  
4.3 Randomization and Blinding  
This is an open- label cross -over study, and neither randomization nor blinding of the 
participant or the  investigator will be employed. The individual evaluating the cervical mucus 
for quality (Insle r score) and the presence or absence of motile sperm in cervical mucus and 
the vaginal pool will be blinded to the study cycle  and use or non- use of the study pr oduct .   
4.4 Prior and Concomitant Medications and illnesses  
Prohibited medications include use of intravaginal products within 72 hours of the expected 
midcycle date, as well as all hormonal contraceptives and presence of or treatment for STIs. 
All concomitant medications will be recorded on CRFs. 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 24 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 5 STUDY DRUG MANAGEMENT  
5.1 Study Drug Formulation 
The ZB -06 drug product is a vaginal film containing 20 mg of the HC4 -N drug substance  and 
additional excipients as described in  Table 1.  
Table 1:  ZB- 06 Product Composition Unit Dosage Form  
Component  Function  Target Quantity per f ilm 
Antibody HC4- N Drug 
Substance  Active  Ingredient  20 mg 
Maltitol  Stabilizer  54 mg 
Histidine  Stabilizer  4.2 mg 
Polysorbate 20 Surfactant  13 µg 
PVA 8 -88 Polymer Base 126 mg 
 
5.2 Study Drug Packaging and Labeling  
The ZB -06 film is packaged in a sealed foil laminate pouch. A representative version of the 
label affixed to the pouch is reproduced below as Figure 1:  
Figure 1: ZB- 06 Film Package Label  
 
5.3 Study Drug Handling and Storage  
The packaged ZB -06 drug product will be shipped and stored at 2- 8° C until dispensed to the 
study participant.  

ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 25 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 5.4 Study Drug Administration 
Participants will insert one ZB -06 film intravaginally approximately 30 minutes prior to sexual 
intercourse  during the product PCT cycle . The film is inserted digitally high in the vagina after 
folding it the  participant’s finger.  
5.5 Study Drug Accountabilit y Procedures  
The ZB -06 film  will be stored in a temperature- monitored, access -controlled refrigerator  at 2-
8 ° C until dispensed by the study staff to the participant at the product cycle  cervical mucus 
check  (CMC) visit (Visit 6) . A log of receipt and dis pensing will be kept by the study staff . 
Unused films will be returned to the Sponsor after study completion. 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 26 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 6 MEASUREMENTS AND EVALUATIONS  
6.1 Efficacy Assessments  
The primary method of evaluating preliminary effectiveness ( primary  objective) for the ZB -
06 film will be the average number  of progressively motile sperm (PMS) in aspirated 
endocervical mucus  examined  across 9 high powered fields ( HPFs ) at 400X magnification at 
100 um sample chamber depth, in the  ZB-06 treatment cycles  comparted to the no product 
treatment cycles .  
The mean, median, standard deviation, and interquartile range (IQR)  of each woman’s average 
number (across 9 HPFs) of progressively motile sperm pe r HPF will be calculated separately 
for baseline and each test PCT. Qualitative assessments of change from baseline, if any, will 
be based on the median and IQR, because of expected non- normality of test cycle data.  
6.2 Safety Assessments 
Tables and listings w ill be created for all TEAEs, defined as those occurring on  or after first 
product use . However, the primary evaluation of safety will be the subpopulation of safety AEs 
that are urogenital, product -related, and/or serious . Data will be presented by presen ce of ZB -
06 film according to relatedness of the finding to study product, whether AEs had onset before 
or after intercourse, and noted by gender , and the severity/seriousness of the AE .  
In addition, concentrations of cytokines and chemokines will be desc ribed at baseline and after 
ZB-06 film use, as a surrogate of subclinical safety endpoints. Safety bloods (hematology, and 
metabolic  panel) will be obtained at screening at Visit 8. U rinalysis will be done at the times 
indicated in the Schedule of Events  (Appendix A ) 
6.3 Pharmacokinetic Assessments  
The concentration of HC 4-N by ELISA, and sperm agglutination titer in serum and 
endocervical mucus, and CV fluid will both be  determined  after each no -product baseline and 
product PCT cycle.  
6.4 Other Assessments  
An acceptability questionnaire will be administered to women and to their male partners at or 
within 72 hours after their product PCT cycle.  
6.5 Study Visits and Procedures  
Prospective participants may be pre -screened; the study will be explained, the inclusion/ 
exclusion criteria reviewed, questions answered, and Visit 1 scheduled. 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 27 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 6.5.1 Visit 1  (Screening)  
• The study and informed consent  form will be reviewed and all volunteer questions will 
be answered.  If the volunteer wishes to participate and meets  the preliminary study 
criteria, she will be asked to review and sign an informed consent form.  The PI or 
designee will sign the form and provide a copy to the participant.  
• The participant will receive an informed consent form to give to her male sexual 
partner.  Study staff  will contact him via telephone or videoconference to go over his 
consent form with him and answer any questions that he has.  If he wants to go over 
the consent form in person, we will make arrangements for him to come to the  clinic.  
The participant  will bring his signed consent form in with her once he has been 
counseled and agrees to sign the consent.  The coordinator who counseled the partner 
and the witness will then sign and date the consent.  Visit 2 procedures will be 
performed  after both partners have provided signatures. 
• An interview  will be conducted to obtain medical history, concomitant medications , 
and demographic information. 
• A urine specimen will be obtained for a urine pregnancy test to confirm that the 
participant is not pregnant and to perform a urinalysis with reflex urine culture.  
Participants with asymptomatic bacteruria do not require antibiotic treatment, as per 
stand ard clinical practice guidelines.  
• An HIV test , chemistry panel, and blood count  will be performed.  
• A physical exam with vital signs will be performed . 
• A pelvic exam will be performed, including:  
o Signs of irritation of the external genitalia, cervix, and va gina, as observed with 
the naked eye will be noted. 
o A sample will be taken for wet mount and vaginal pH if indicated.   
o Specimens for Trichomonas vaginalis, Neisseria gonorrhea and Chlamydia 
trachomatis will be collected . 
o A Pap smear will be performed, if necessary, as consistent with standard 
medical practice as outlined in the study manual  and inclusion criteria.  
• Film insertion training:   
o The investigator or designee will explain to the participant how to insert a 
market ed vaginal film with similar dimensions and physical character to the 
ZB-06 study film (Vaginal C ontraceptive Film (VCF) , Apothecus 
Pharmaceutical Corporation). The participant will then attempt to insert a VCF  
film without assistance.   
o If insertion by the participant is unsuccessful, the investigator will attempt to 
determine what is causing the problem and will reinstruct and assist as needed.  
The participant may be asked to try different positions (standing, squatting, 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 28 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 standing with one leg raised, etc .) for insertion.  If the participant can insert the 
film, the investigator will remove the film once proper placement is confirmed.   
o If the investigator determines that the participant cannot insert the surrogate 
VCF  correctly, then the participant will not continue in the study. 
• UTI, vaginal candidiasis, and symptomatic bacterial vaginosis (BV) infections will be 
treated, preferably with oral medication. If the participant is otherwise eligible, she will 
continue in the study. 
• Provided no abnormalities are found on pelvic examination, no information contained 
in the medical history excludes the volunteer from participating in the study, and she 
has demonstrated the ability to insert  a surrogate film , the participant will be continued 
in the  study.   
• Participants  will be given a supply of non- spermicidal, lubricated condoms for use 
during certain times of the study. 
• The participant will be instructed to call the coordinator at the start of her next menses.  
At that time, the participant will be informed of the results of any laboratory tests that 
were not available at the enrollment visit.  She will be instructed that her male partner 
will need to use non- lubricated condoms for any acts of intercourse after her next 
menses, up until approximat ely 72 hours prior to the cervical mucus check visit.  The 
couple should abstain from intercourse for 72 hours prior to the predicted midcycle 
point.   
 
6.5.2 Visit 2  (Enrollment)  
• This visit will occur in the follicular phase of the menstrual cycle, preferably after 
menses ceases , on or before menstrual cycle day 10. 
• Screening laboratory tests will be reviewed, along with the results of other inclusion 
and exclusion criteria, and eligible participants will be enrolled by entry into the 
Enrollment Log. 
• She will be  asked if there are any new or worsening medical problems or symptoms or 
used any medications since the last study visit.  In addition, the participant  will be asked 
if her male partner has had any adverse events (AEs) involving the urogenital system 
or wh ether he has had any serious AEs.  
• She will be provided with an ovulation predictor kit (OPK) to help determine her 
midcycle point.  Instructions for the proper use of the kit will be provided.  Participants 
will be instructed to begin daily urine testing o n day 10 of their cycle (adjusted as 
needed to their normal cycle length) and to contact the study coordinator if an OPK test 
is positive .  Her mucus check visit will then be scheduled for the day of the positive 
test (preferred) or the next day at the lat est.  If the participant does not have a positive 
urine LH test by day 22, she will be considered anovulatory for this cycle.  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 29 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 • The participant will be instructed that from the start of her menses until 72 hours before 
her expected midcycle, she and her part ner should use study- provided condoms for 
each act of intercourse. Th ere should be no intercourse, use of intravaginal products  
(including spermicide) and her male partner should not have an ejaculation within 72 
hours of expected mid- cycle date (visits 3, 6 and 9) . 
 
6.5.3 Visits  3, 6 and 9 (CMC Baseline [ no product ] Cycle, CMC ZB-06 Cycle, CMC post-
product -use safety  Cycle ) 
This visit will be conducted on the day of ovulation or the day before or after, as determined 
by calculation or as identified by the presence of a positive test result with the OPK, whichever 
comes first.  
• An interval history will be collected. Entry criteria will be reviewed to confirm the 
participant’s eligibility.  
• The participant will be asked if she has any new or worsening medical problems or 
symptoms or used any medications since the last study visit.  In addition, she will be 
asked if her partner has had any AEs involving the urogenital system and whether he 
has had any serious AEs.  
• The participant will be asked whether she r efrained from intercourse and the use of 
intravaginal products and whether her male partner refrained from ejaculation during 
the previous 72 hours. If instructions were not followed, she will be reinstructed. If she 
used a spermicide or spermicidally lubr icated condom during the previous 72 hours, 
the visit will be rescheduled in the next cycle. Otherwise, the visit may continue at the 
investigator’s discretion.  
• Urine will be obtained for urinalysis and reflex urine culture  at visits 3 and 6.   
• A urine pregnancy test will be performed at visit 6 
• A blood sample (approximately 3 teaspoons) will be obtained at visits 6 and 9. The 
participant will undergo a pelvic exam during which a sample of cervical and vaginal 
secretions will be examined for midcyc le characteristics and the presence of sperm.  At 
visits 3 and 6, a colposcopy exam of the cervix and vagina will be done to determine if 
there are s igns of irritation of the external genitalia, cervix, and vagina, as observed 
with the naked eye will be noted.   
• Vaginal pH will be determined at visits 3 and 6.  A slide for Nugent score will be 
obtained at visit 6  
• A speculum exam will be performed and vaginal swabs, aspirate, endocervical mucus 
and a cervicovaginal fluid lavage (CVL) will be obtained.  
• If sperm are found in the vagina or cervical mucus, the baseline cycle will be 
rescheduled for the following month and instructions on the use of condoms and 
avoidance of ejaculation will be reviewed.  Longer abstinence may be recommended 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 30 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 for co uples that have reportedly complied with the required 72- hour period.  Additional 
supplies will be provided as needed.   
• If the cervical mucus score is <10, the participant may be asked to return in 1 or 2 days 
if it seems likely that the midcycle point ha s not yet been reached, or in the next cycle 
if it seems likely that the midcycle point has already passed.  
• If no sperm are detected at this visit, and the cervical mucus score is ≥10, the participant 
will be instructed to return home and have intercourse without a condom 2 to 3 hours 
prior to Visits 4, 7 or 10, which will be scheduled for the same or following day, within 
27 hours of the mucus check visit.   
• At visit 6, we will provide the participant with a ZB -06 film to use  and instruct her  to 
insert the  film deep in to the vagina about 30 minutes prior to intercourse.  A back up 
film may also be provided upon participant request or at the discretion of the 
investigator.   
• A directed physical exam will be performed if indicated.  
• The participant will be in structed to ask her partner, prior to her next visit, if he has had 
any AEs involving the urogenital system or whether he has had any serious AEs. 
 
6.5.4 Visits 4, 7, 10 (PCT Baseline Cycle, PCT ZB-06 Cycle and  post-product -use safety 
cycle  
The participant will return to the clinic 2 -3 hours after coitus ends and within 27 hours of the 
mucus check visit  (above, visits 3, 6 and 9) . 
• The participant will be asked if she has any new or worsening medical problems or 
symptoms or used any medications since the last study visit.  In addition, she will be 
asked if her partner has had any AEs involving the urogenital system or associated with 
the use of study products (as applicable) and whether he has had any serious AEs. 
• A blood sample (approximately 2 teaspoons ) will be  obtained at visit 7. 
• A wet mount or urine dipstick, or other tests, will be performed if indicated.  If the test 
is positive for candidiasis, BV, or UTI the participant will be treated, preferably with 
oral medication, and continued in the study. 
• Vaginal swabs  or aspirate, and endocervical mucus will be obtained.     
• The participant will again undergo a pelvic exam during which a sample of cervical 
and vaginal secretions will be evaluated for midcycle characteristics and the presence 
of sperm.  At visits 4  and 7, a colposcopy exam of the cervix and vagina will be 
performed to observe if there are s igns of irritation of the external genitalia, cervix, and 
vagina will be noted as observed with naked eye.  Baseline PCT results will be 
interpreted and managed as listed in  Appendix B . 
• A directed physical exam will be performed if indicated.  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 31 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 • If the participant uses the study product prior to intercourse and intravaginal ejaculation 
cannot be achieved by the male, due to reasons such as, but not limited to:  erectile 
dysfunction, inability to ejaculate, illness , etc., the study team will contact the sponsor 
and discuss if the participant may be offered a second chance at a product use cycle 
with a second exposure to the vaginal film, i n a subsequent menstrua l cycle.   The 
participant  will not present to the clinic for visit 7 in the current cycle.  
• If the participant is  willing and able to participate in a second product use cycle, after 
a failed first attempt, they will continue in the study with the intent of  completing all 
10 study visits.  
If the participant and their  partner do not want to attempt a second product use cycle, or if the 
sponsor does not allow this, the participant  will be asked to return for visit 8 after which they  
will be exited from the stu dy. 
6.5.5 Visits 5 and 8 (24 hours post PCT safety checks)  
• The participant will be asked if she has any new or worsening medical problems or 
symptoms or used any medications since the last study visit.  In addition, she will be 
asked if her partner has had any A Es involving the urogenital system or associated with 
the use of study products (as applicable) and whether he has had any serious AEs. 
• A colposcopy assessment will be performed  
• Vaginal swabs  or aspirate, endocervical mucus and a cervicovaginal fluid lavage 
(CVL) will be obtained.  
• A blood sample (approximately two teaspoons) will be obtained. 
• Urine will be obtained for urinalysis and reflex urine culture.  
• Vaginal pH and slide for  Nugent score wil l be obtained at visit 8.  
• At the end of Visits 5 and 8, the participant will be given additional condoms if needed 
and instructed to contact the study coordinator on the first day of her next menses at 
which time instructions regarding sexual activity and checking urinary LH will be 
given.  The participant wi ll be reminded that from the start of her menses until 
menstrual cycle day 10 , she and her partner should use study provided condoms for 
each act of intercourse. There should be no intercourse or use of intravaginal products 
(including spermicide) after menstrual cycle day 10 . 
• The participant will be provided with a new ovulation prediction kit.  When she 
contacts the clinic on the first day of her next menses, she will be instructed to begin 
daily urine testing starting on day 10 of her cycle .  She will be  instructed to contact the 
study coordinator if a urine  test result is positive .  Her test cycle mucus check visit will 
be scheduled for the day of the positive test (preferred) or the next day at the latest.  
However, if she has not had a positive urine t est result by day 22, she will be considered 
anovulatory and will either be discontinued from the study or allowed to try another 
cycle, depending on ZabBio, Inc. and investigator discretion. 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 32 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 • A wet mount or urine dipstick, or other tests, will be performed if indicated.  If the test 
is positive for candidiasis, BV, or UTI the participant will be treated, preferably with 
oral medication, and continued in the study. Note that these vaginal infections may be 
treated with vaginal medication subsequent to 24 hr check visits.  
• At visit 8, the participant will fill out an acceptability questionnaire.  
• At visit 8 arrangements will be made to contact the participant’s sexual partner within 
the next 48 hours (within approximately 72 hours from intercourse) for him to answer 
male acceptability questionnaire questions . 
 
6.6 Visit Windows  
• Visit 2 must be within 35 days of Visit 1.  
• Visits 3, 6, and 9 (CMC visits) timing is determined according to midcycle timing 
according to calculations and/or OPK  testing results rather than visit windows.  
• Visits 4, 7, and 10 (PCT visits) must be between 2 and 3 hours after intercourse, with 
intercourse  timing determined by the findings at the preceding CMC visit.  
• Visits 5 and 8 (24 hour assessments after the baseline and product PCT visit) mus t be 
within 4 hours either side of that scheduled 24 hour follow up time.  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 33 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 7 DATA ANALYSIS METHODS  
7.1 Data Management  
Data Management will be overseen by Joseph Politch, PhD of BUSM (Lead Data Manager), 
via a 21CFR11 compliant electronic database ( StudyTRAX ®; ScienceTRAX, Macon, GA) 
with direct data entry via secure web portal. Database construction and validation will be 
performed in coordination with the Biostatistics and Epidemiology Data Analytics Center 
(BEDAC) at Boston University School of Public Health. Data analysis will be performed by 
Howard Cabral, PhD, Professor of Biostatistics at the Boston University School of Public 
Health.  
7.2 Sample Size Determination  
To assess the primary endpoint (number of progressively motile sperm in aspirated 
endocervical mucus 2 -3 hours after sexual intercourse), fifteen couples are planned to complete 
both the baseline and the product PCT visits. We calculate that this sample size will provide a 
power of 90% to detect a clinically significant (10- fold) reduction of progressively motile 
sperm per high power field, from a mean of 17 in baseline no- product cycles (Archer et al., 
1995; Mauck et al., 1997; Mauck et al., 2004; Burke et al., 2010; Mauck et al., 2017) to <1.7 
progressively motile sperm per high power fie ld (PMS/HPF) using study product. 
7.3 Subject Populations for Analysis  
Data from all women who complete both the baseline and the product PCT visits will be 
analyzed in the effectiveness analysis , thus including all women exposed to product . Data from 
all part icipants who receive the study product will likewise be included in the safety analysis.   
7.4 Interim Analysis  
No interim analyses are currently planned.  
7.5 Statistical Analysis  
Participants will be considered evaluable if they comple te both the baseline and product PCT 
visits . If necessary, we will seek to recruit additional  participants to achieve a total of 15 
evalu able participants.  
7.5.1 Primary Endpoint:  
The endpoint  for the primary objective (surrogate for contraceptive efficacy) will be the 
average number o f PMS ( across 9 HPF) in aspirated endocervical mucus 2 -3 hours after sexual 
intercourse without study product versus with study product.  A 10- fold or greater reduction in 
PMS from baseline will be considered indicative of likely contraceptive effect based  on prior 
experience with detergent spermicides and with cervical barrier devices ( Mauck et al., 1997b; 
Mauck et al., 1997c ; Mauck et al., 2004; Amaral et al., 2004; Archer et al., 1995; Mauck et 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 34 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 al., 1996; Archer et al., 1997; Schwartz et al., 2008; Mauck et al., 2017) . Therefore, the main 
comparison of interest for the primary endpoint will be baseline [2- 3 hours after intercourse 
without product use (Visit 4)] vs. post study product [2- 3 hours after intercourse with product 
use (Visit 7)]. Fo r comparison of the two time points, the Wilcoxon Signed Rank Test will be 
utilized . 
An additional categorical analysi s will compare the proportion of women with an average (also 
across 9 HPF) of fewer than 5 PMS/HPF, calculated separately for each test cy cle to the 
proportion of women with ≥5 PMS/HPF at baseline [2-3 hours after intercourse without 
product use (Visit 4)]  vs. post study product [ 2-3 hours after intercourse with product use (Visit 
7)].  For this analysis, the McNemar’s test will be used.  
 
7.5.2 Secondary Endpoint:  
The secondary endpoint will be the incidence of Grade 2 or greater adverse events  in the 
participant and her male partner in the interval between the baseline intercourse without 
product  (Visit 4)  and Visit 6, in comparison to the incidence of Grade 2 or greater adverse 
events  in the interval between intercourse with product use (Visit 7) and Visit 9.  Additional  
related  analyses will include the incidence of total  adverse events in the participant and  her 
male partner in the interval between the baseline intercourse without product  (Visit 4)  and Visit 
6, in comparison to the incidence total  adverse events in the interval between intercourse with 
product use  (Visit 7)  and Visit 9 , as well as comparisons  of adverse event severity in the two 
intervals. For comparison of the two intervals , the Wilcoxon Signed Rank Test will be utilized.   
An assessment of relatedness to study product will be made for adverse events as supplemental 
information. Adverse event evaluations will include symptoms, epithelial defects assessed by 
colposcopy, and laboratory safety blood tests. Emphasis will be placed on adverse events that 
are urogenital, product -related and/or serious among female and male participants. 
 
7.5.3 Exploratory Endpoint s: 
Exploratory endpoints will include the following:  
1. Antisperm antibody concentrations in vaginal fluid measured by ELISA at baseline, 
at 2-3 hours and at 24 hours after intercourse with and without product use and at 1 
month after product (ZB-06 film) use.  
2. Sperm agglutination titer in vaginal fluid measured by endpoint dilution at baseline, 
and at 2 -3 hours and at 24 hours after intercourse with and without product used, 
and at 1 month after product use. 
3. Concentrations of antisperm antibody in endocervical mucus  samples measured by 
ELISA  at baseline, and at  2-3 hours and at  24 hours after intercourse  with and 
without product use, and at 1 month after product use. 
4. Sperm agglutination titer in endocervical mucus  measured by endpoint dilution at 
baseli ne, and at  2-3 hours and at  24 hours after intercourse  with and without 
product use, and at 1 month after product use.  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 35 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 5. Concentrations of antisperm antibodies  in serum , and measured by ELISA  at 
baseline, at  24 hours, and at 1 month after exposure to ZB -06 film.  
6. Sperm agglutination titer in serum  by endpoint dilution measured at baseline, and 
24 hours and 1 month after exposure to ZB -06 film . 
7. Concentrations of immune mediators in cervicovaginal lavage  measured via 
multiplex assays at baseline and at 24 hours after intercourse with and without 
study product. 
8. Vaginal  pH at baseline and 24 hours after intercourse with vs. without study 
product. 
9. Nugent Score at Visit 6 baseline and 24 hours after intercourse with study product. 
 
The continuous variables described in the Exploratory Endpoint section will be analyzed as 
follows:  For two time point comparisons, the Wilcoxon Signed Rank Test will be utilized; for 
three time point comparisons, mixed linear model analysis will be performed. If dependent 
variables are not normally distributed, they will be (natural) log transformed prior to mixed 
linear model analysis. A significant effect will be followed by Tukey- Kramer multiple 
comparison tests. The mixed linear model analysis accounts for missing values should some 
participants fail to return for the 1 month time point. Statistical significance will be assumed 
when p<0.05. All analyses will be performed with SAS (Version 9.4; SAS Institute Inc., Cary, 
NC, USA).    
 
An equivalence test will be performed between the average number of PMS ( across 9 HPF) in 
aspirated endocervical mucus 2- 3 hours after sexual intercourse without study product at 
Baseline (Visit 4) versus the average number of PMS ( across 9 HPF) in aspir ated endocervical 
mucus 2- 3 hours after sexual intercourse without study product one month following exposure 
to study product (Visit 10). The purpose of this test is to determine whether the postcoital PMS 
concentrations one month following product exposure are equivalent to baseline levels. The 
equivalence test will be performed utilizing the two one -sided t -tests (TOST) procedure.  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 36 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 8 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
The investigator is responsible for the detection and documentation of events meeti ng the 
definition of an AE or serious adverse event (SAE) as provided in this protocol.  AE event 
monitoring for this study will begin at  the time of informed consent (Visit 1) through the last 
visit or follow up phone call .  In order to fulfill safety reporting obligations, the investigator 
should promptly report any SAEs resulting from study participation. 
8.1 Definition of an AE  
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product, regar dless of the suspected causal relationship with the study 
treatment.  An AE can therefore be any unfavorable and unintended sign (including a clinically 
significant abnormal laboratory finding), symptom or disease temporally associated with the 
use of a medicinal product, whether or not considered related to the use of the medicinal 
product. 
The definition of an AE includes:  
• An exacerbation of a pre -existing illness  
• An increase in the frequency or intensity of  a pre- existing episodic event or condition 
• Any condition detected or diagnosed after the start of study treatment even though the 
condition may have been present prior to the start of the study 
• A continuous persistent disease or symptom present at baseline that worsens after the 
start of the study 
The definition of an AE does not include:  
• A medical or surgical procedure such as surgery, endoscopy, tooth extraction, or 
transfusion (although the condition that leads to the procedure may be an AE)  
• A pre -existing disease or condition present at the start of  the study that does not worsen 
during the study 
• Any situation where an untoward medical occurrence has not occurred (for example, 
hospitalizations for cosmetic elective surgery or social admissions)  
• An overdose of either the study drug or a concurrent medication without any resulting 
signs or symptoms  
AEs may also include post -treatment events that occur as a result of protocol -mandated 
procedures (e.g., invasive procedures or modification of a subject's previous therapeutic 
regimen).  
8.2 Definition of an SAE  
A serious adverse event (SAE) is an AE which meets any of the following criteria:  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 37 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 • Results in death  
• Is life -threatening  
• Requires hospitalization or the prolongation of existing hospitalization  
• Results in a persistent or significant disability or incapacity  
• Is a congenital anomaly or birth defect  
In addition, important medical events that may not result in death, be life -threatening, or 
require hospitalization may be considered serious when, based on appropriate medical 
judgment, the investigator determines that the event may jeopardize the subject and may 
require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
Examples of such medical events include allergic bronchospasm requiring intensive treatment 
in an emergency room or at home, blood dyscrasias, or convulsions that do not result in 
hospitalization, or the development of drug dependency or drug abuse.  
Hospitalization for elective treatment of a pre -existing condition that did not worsen during the 
study is not considered an AE.  Any complications that occur during hospitalization are AEs.  
If a complication prolongs hospitalization, then the complicating event is an SAE. 
Life-threatening means that the subject was, in the view of the investigator, at i mmediate risk 
of death from the event as it occurred.  It does not mean that the event, had it occurred in a 
more severe form, might have caused death. 
8.3 Clinical L aboratory Abnormalities and Other Abnormal Assessments  
Abnormal laboratory findings or other a bnormal assessments (e.g., ECGs, vital signs) that are 
judged by the investigator as clinically significant should be recorded as AEs.  Clinically 
significant abnormal laboratory findings or other abnormal assessments that are detected after 
the start of s tudy treatment, or that are present before the start of study treatment and worsen 
after study treatment, are considered AEs. 
Clinically significant abnormal laboratory findings or other abnormal assessments that are 
associated with a disease (unless judge d by the investigator as more severe than expected for 
the subject ’s condition) or that are present before the start of study treatment and do not worsen 
after study treatment are not included as AEs.  
The investigator should exercise his or her medical and scientific judgment in deciding whether 
an abnormal laboratory finding or other abnormal assessment is clinically significant. 
8.4 Method, Frequency, and Time Period for Detecting AEs and SAEs  
Each subject will be monitored for AEs from the time of informed c onsent ( Visit 1) through 
their last visit or follow up phone call .  All AEs and SAEs, regardless of attribution (i.e., 
relationship to study drug), will be collected during this time period.  The collection period 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 38 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 will end when the subject completes the Follow -Up phone call  unless there is an ongoing AE 
which requires monitoring beyond this time point.  
8.5 Documenting AEs and SAEs  
All AEs that occur during the study should be documented in the subject ’s source documents 
in accordance with the investigator ’s nor mal clinical practice and in the AE section of the CRF.  
The following information about each AE should be recorded in the source documentation and 
in the CRF:  
• Dose of study drug  
• Onset and cessation times  
• Severity  
• SAE (yes or no)  
• Relationship to study drug 
• Action taken in response to the event  
Assessments of AE severity and of the possible relationship to study drug will be made by the 
investigator. 
The investigator should attempt to establish a diagnosis of the event based on signs, symptoms, 
and other clinical information.  Whenever possible, a diagnosis should be reported as the AE 
rather than just a sign or symptom.  If a clinically significant abnormal laboratory finding meets 
the definition of an AE, a diagnosis or any clinical signs and symptoms rather  than the 
abnormal laboratory finding should be recorded if possible.  If no diagnosis is known and 
clinical signs and symptoms are not present, then the abnormal finding should be recorded as 
the AE.  
8.6 Follow -Up of AEs and SAEs  
All AEs must be followed unti l resolution, until the condition stabilizes, until the event is 
otherwise explained or is judged by the investigator to be no longer clinically significant, or 
until the subject is lost to follow -up.  The investigator is responsible for ensuring that foll ow-
up includes any supplemental investigations necessary to elucidate as completely as practical 
the nature and/or causality of the AE.  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with ot her health care 
professionals.  
ZabBio, Inc. may request that the investigator perform or arrange for the conduct of 
supplemental measurements and/or evaluations of an AE.  If a subject dies during participation 
in the study or during a recognized follow -up period, then ZabBio, Inc. should be provided 
with a copy of any post -mortem findings, including histopathology.  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 39 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 8.7 SAE Reporting  
Any SAEs or Adverse Event of Interest should be reported within 24 hours of the investigator 
becoming aware of the occurrence, regardless of expectedness or causality.  The investigator 
must call and then email  the completed Serious Adverse Event Form to the contact information 
listed below.  
The SAE form should be completed as thoroughly as possible and signed by the investigator 
or his/her designee before transmittal to the Sponsor/ ZabBio, Inc.’s designee.  It is  very 
important  that the investigator provide his/her assessment of causality to Study Treatment at 
the time of the in itial SAE report.  
SAE Reporting Contact Information  
Primary Medical Monitor:  
 Thomas Moench  
thomas.moench@mappbio.com  
Phone:  443-900-6696  
Alternate Phone:  410-828-4358  
 
The Site Investigator will also forward an electronic copy of the SAE Report and supporting 
documentation (including discharge summaries progress notes, laboratory results) to the study 
team contacts via e- mail within 24 hours of receipt.  
The site PI will perform a clinical re view of the information provided to identify any missing 
data.  The  Site Investigator will also contact the study site to clarify any discrepant or missing 
information, to answer questions and to provide guidance to the site, if needed.  The 
Investigator w ill be instructed to report the SAE as an acceptable medical diagnosis.  If a 
preliminary diagnosis has not yet been made, then each symptom will be listed separately.  A 
follow -up report will be issued when a diagnosis is made. 
An updated SAE Report shoul d be emailed  within 48 hours of receipt of new or updated 
information.  The investigator must also promptly notify the Institutional Review Board 
(IRB)/Independent Ethics Committee (IEC) of the occurrence of an SAE, including any 
follow -up information.  
ZabBio, Inc. has a legal responsibility to notify regulatory authorities about the safety of a drug 
under clinical investigation.  If a given SAE is considered related to the use of study medication 
and is unexpected, ZabBio, Inc. will forward a report of the  event to the relevant regulatory 
health authority and to all investigators.  It is the investigator’s responsibility to promptly 
inform the IRB/IEC in accordance with local regulations. 
An SAE that is considered related to study participation (e.g., as the result of any study 
procedures or invasive tests), even if it occurs during Screening or after the Follow -Up Visit, 
should be reported promptly to ZabBio, Inc . 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 40 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 8.8 Post-Study AEs and SAEs  
Investigators are not obliged to actively seek AE information from for mer study participants.  
However, if the investigator learns of an SAE at any time after a subject has been discharged 
from the study and the event may reasonably be considered related to the use of study drug, 
the investigator should promptly telephone ZabBio, Inc.  
8.9  Pregnancies  
Participants are required to be protected from pregnancy by female surgical  sterilization. 
However, s hould a pregnancy occur, it must be reported as soon as possible to the Sponsor or 
designee and recorded on the pregnancy CRF . The participant will be discontinued from the 
study and appropriate exit procedures will be followed. Note that pregnancy in itself is not 
regarded as an AE unless there is a suspicion that an investigational product may have 
interfered with the effectiv eness of a contraceptive medication. If the participant has been 
exposed to study product, the course of the pregnancy should be followed until it has an 
outcome (spontaneous miscarriage, elective termination, normal birth or congenital 
abnormality). If the participant seeks care outside the site, every effort should be made to obtain 
her consent for the site to receive a copy of her medical records related to the pregnancy, its 
outcome and the health of the neonate, if applicable. 
Reports of congenital abnormalities/birth defects are SAEs. Spontaneous miscarriages should 
also be reported and handled as SAEs. Elective abortions without complications should not be 
reported as AEs.  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 41 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 9 STUDY ADMINISTRATION 
9.1 Safety monitoring  
9.1.1 Protocol Safety Review Team (PSRT)  
The study site investigators are responsible for continuous close safety monitoring of all study 
participants, and for alerting the Protocol Team and IRB if unexpected concerns arise. A sub-
group of the Protocol Team, including the Medical Safety Officer, the Sponsor Project 
Physician, and the Site Investigator will serve as the Protocol Safety Review Team (PSRT). 
The PSRT and the study site will cooperate closely to monitor participant safety and respond 
to occurrences of toxicity in a timely manner. The f ollowing findings will serve as the 
minimum criteria to pause or stop enrollment in the study. However , the National Institu tes of 
Health (NIH)  and/or the PSRT can stop the study at any time for any concerning findings of 
lesser severity than those listed here:  
1. If any participant manifests a grade 3 or higher AE that is judged to be related to study 
product . 
2. If any participant develops deep epithelial disruption or ulceration of the genital 
epithelium.  
3. If any participant develops erythema or edema of more than 50% of the combined 
vaginal and cervical surface (grade 2) or more than 50% of the vulvar surface (grade 
2).  
If enrollment is paused, its reinstitution will require the unanimous agreement of all members 
of the PSRT. 
9.1.2 Clinical D ata S afety R eview  
The Data Management Team will generate data summaries for the PSRT  after 8 couples have 
completed Study Visit 8 . These data summaries will include adverse event, accrual and 
retention data. The Medical Safet y Officer (or designee) will evaluate adverse event data 
independently and present those to the PSRT  at this interim review, or at any time that 
significan t safety concerns arise. The PSRT will determine whether or not the study protocol 
should continue as  originally designed, should be changed, or should be terminated. 
The IRB will be notified of any serious and unexpected adverse events according to the policies 
outlined in the EVMS  IRB Policy and Manual of Operations.  
9.2 Data Handling and Recordkeeping  
9.2.1 Study D ata  
Study data will be collected in an electronic database (S tudy- TRAX®) on direct web -portal -
entry CRFs, via a study laptop. The database will reside on servers at Biostatistics and 
Epidemiology Data Analytics Center (BEDAC)  Boston University School of Public Health . 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 42 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 These eCRFs will serve as source data. Insler score data, and sperm motility and enumeration 
data from cervical mucus and vaginal pool samples will be initially recorded on a laboratory 
form, and transferred to a corresponding eCRF, but in this case, the laboratory form will serve 
as source data.   
9.2.2 Source Documentation 
Study documentation includes all case report forms, data correction forms, electronic data files, 
workbooks, source documents, monitoring logs, appointment schedules, ZabBio, Inc.-
investigator correspondence and regulatory documents (e.g., signed protocol and amendments, 
IRB correspondence and approved consent form and signed patient consent forms, Statement 
of Investigator form, and clinical supplies receipt and distribution records).  
Source documents include all recordings of observations or notations of clinical activities and 
all reports and records necessary for the evaluation and reconstruction of the clinical research 
study.  Source documents include, but are not limited to, laboratory reports, ECG tracings, X -
rays, radiologist reports, patient diarie s, ultrasound photographs, patient progress notes, 
hospital charts, pharmacy records and any other similar reports or records of any procedure 
performed in accordance with the protocol. 
Whenever possible, the original recording of an observation should be retained as the source 
document; however, a photocopy is acceptable provided that it is a clear, legible, and exact 
duplication of the original document. 
9.3 Regulatory and Ethical Considerations  
9.3.1 Regulatory Authority Approval and Study Conduct  
In accordance wi th all applicable national regulations, ZabBio, Inc. will obtain regulatory 
approval prior to initiating the study. 
The clinical trial described in this protocol will be conducted in compliance with the current 
revision of the Declaration of Helsinki, Inte rnational Conference on Harmonization (ICH) 
guidelines for Good Clinical Practice (GCP), and applicable local regulatory requirements.  
9.3.2 Institutional Review Board/Independent Ethics Committee Approval  
It is the investigator's responsibility to ensure that t he protocol (and any protocol amendment, 
if applicable) is reviewed and approved by an appropriate IRB/IEC. 
The IRB/IEC must also review and approve the site's ICF and any other written information 
provided to the subjects, including any advertisements to be used for subject recruitment.  The 
investigator or a designee must forward to ZabBio, Inc. or its representative copies of the 
IRB/IEC approval and the approved informed consent materials prior to the enrollment of any 
subjects in the study. 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 43 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 If it is ne cessary to amend either the protocol or the ICF during the study, the investigator will 
ensure that the IRB/IEC reviews and approves all amended documents.  IRB/IEC approval of 
the amended ICF must be obtained before any subjects consent to take part in the study using 
this version of the form.  Copies of the IRB/IEC approval of the amended protocol or ICF must 
be forwarded to ZabBio, Inc. or its representative as soon as available.  
9.3.3 Subject Informed Consent  
The investigator or designee will inform potential subject s of all study requirements and the 
risks and benefits pertaining to participation in the study.  The process for obtaining subject 
informed consent will be in accordance with all applicable regulatory requirements.  
The investigator or a designee and the subject must both sign and date the ICF before the 
subject can enroll in the study or any study related procedures may be conducted.  The subject 
will receive a copy of the signed and dated ICF; the original ICF will be retained in the sit e 
study records.  
The decision to participate in the study is entirely voluntary.  The investigator or a designee 
must emphasize to the subject that consent regarding study participation may be withdrawn at 
any time without penalty or loss of benefits to which the subject is otherwise entitled.  
9.3.4 Investigator Reporting Requirements  
In accordance with regulatory requirements, the investigator may be obliged to provide 
periodic safety updates on the conduct of the study at the site and notification of study clos ure 
to the IRB/IEC.  Such periodic safety updates and notifications are the responsibility of the 
investigator. 
9.4 Amendment of the Protocol  
Changes to the protocol during the study will be documented as amendments.  These will form 
an integral part of the pr otocol and will be signed by the relevant personnel at ZabBio, Inc., 
and by the investigator(s). 
Depending on the contents of the amendment and local legal requirements, the amendment 
will be submitted to the IRB/IEC and, where necessary, to the relevant c ompetent authorities.  
The investigator should not implement any deviations from, or changes to the protocol, without 
agreement by ZabBio, Inc. and prior review and documented approval/favorable opinion of 
the appropriate IRB/IEC and, if legally required, c ompetent authorities, except where 
necessary to eliminate an immediate hazard to the subjects.  
If an amendment substantially alters the study design, increases the potential risk to the subjects 
or affects the treatment of the subject, then the ICF must be  revised and submitted to the 
IRB/IEC, and where necessary, to the relevant competent authorities, for review and approval.  
When a subject is currently undergoing study procedures and is affected by the amendment, 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 44 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 then the subject must be asked to consent  again using the new ICF.  The new ICF must be used 
to obtain consent from new subjects prior to conducting any study- related activities.  
9.5 Subject Data and Data Protection  
Permission for direct access to subject’s data will be sought in writing by the inves tigator and 
from the subject as part of the informed consent procedure.  This gives permission to examine, 
analyze, verify, and reproduce any records and reports that are important to the evaluation of 
the study.  Any party (e.g., domestic and foreign regulatory authorities, clinical research 
associates and auditors) with direct access must take all reasonable precautions within the 
constraints of the applicable regulatory requirement(s) to maintain the confidentiality of the 
subject’s identities and ZabBio , Inc. ’s proprietary information. 
It is the investigator’s responsibility to ensure that each subject has consented, in writing, to 
direct access.  The clinical research associate will verify that this has occurred.  
The investigator must ensure that the documents that are given to ZabBio, Inc. or its 
representatives do not contain the name or address of the subject, or other information that 
would affect the anonymity of the subject (apart from his/her initials). 
9.6 Study Personnel and Study Monitoring  
The ZabBio, Inc. should ensure that it is specified in the protocol or other written agreement 
that the investigator(s)/institution(s) will permit trial- related monitoring, audits, IRB/IEC 
review, and regulatory inspection(s), providing direct access to source data/documents.  
ZabBio, Inc. or a ZabBio, Inc. appointed monitor will visit the site in person, or remotely prior 
to the start of the study to discuss the protocol and data collection procedures with site 
personnel.  
Study monitoring will continue to be conducted on a regular basis to verify that the study data 
are authentic, accurate and complete, to ensure that the safety and rights of subjects are being 
protected and to verify that the study is conducted in accordance with the currently approved 
protocol, GCP, and all applicable regulatory requirements.  A monitor will periodically contact 
the study site during study conduct and will conduct regular on- site or remote visits.  The 
extent, nature, and frequency of on -site visits will be based on such consider ations as the study 
objective and endpoints, the purpose of the study, study design complexity, and enrollment 
rate.  During site visits, the monitor will:  
• Assess the progress of the study 
• Review all study data collected  
• Determine if study data are entered  completely and accurately in the CRFs  
• Conduct source document verification  
• Confirm that ICFs for all subjects are present and accurately completed  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 45 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 • Identify any study conduct issues and address their resolution 
The investigator agrees to allow ZabBio, Inc. and the monitor direct access to all relevant 
documents and to allocate his or her time, and that of the study staff, to discuss any findings 
and relevant issues.  
At study closure, the monitor will also conduct all activities indicated in Section  9.8, Study 
Site Closure.  
9.7 Quality Assurance  
At its discretion, ZabBio, Inc. or its representative may conduct a quality assurance audit of 
this study.  Also, regulatory agencies may conduct a regulatory inspection of this study.  If 
such audits or regulatory inspections occur, the investigator agree s to allow direct access to all 
relevant documents and to allocate his or her time, and that of the study staff, to the auditor or 
inspector to discuss any findings and relevant issues. 
9.8 Study and Site Closure  
Upon completion of the study, the following act ivities, when applicable, must be conducted by 
ZabBio, Inc. or it’s designee in conjunction with the investigator, as appropriate:  
• Accounting, reconciliation, and final disposition of used and unused study drug and 
study drug containers;  
• Return of all study data to ZabBio, Inc. or designee;  
• Completion of any remaining data clarifications and/or other data resolutions;  
• Review of site study records for completeness;  
• Ship blood samples to the respective laboratories, if applicable, in accordance with the 
instructions described in the Study Reference Manual provided for this study. 
ZabBio, Inc. reserves the right to temporarily suspend or prematurely discontinue this study at 
any time and for any reason.  The study will be suspended or terminated if continuation of the 
study represents a serious medical risk to the subjects in the opinion of the investigator or 
ZabBio, Inc.  Other possible reasons for study discontinuation include, but are not limited to: 
the occurrence of an SAE or other AE unacceptable in natur e, severity, or frequency to the 
investigator or ZabBio, Inc., a failure to observe GCP, or an inadequate level of subject entry.  
If the study is suspended or discontinued early, ZabBio, Inc. will inform the investigator of the 
reason for taking such action.  ZabBio, Inc. will also promptly inform the regulatory authorities 
of the suspension or termination of the study and the reason.  If required by applicable 
regulations, the investigator must inform the IRB/IEC promptly and provide the reason for the 
suspension or termination. 
If the study is prematurely discontinued, all study data must be returned to ZabBio, Inc.  In 
addition, the study site must conduct final disposition of all unused study drug in accordance 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 46 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 with ZabBio, Inc.’s procedures for the study.  Financial compensation to investigators and/or 
institutions in this instance will be in accordance with the agreement established between the 
investigator and ZabBio, Inc.  
9.9 Records Retention  
In accordance with applicable regulatory requirements, the investigator will maintain a copy 
of all site study records in a safe and secure location.  After completion of the study, a copy of 
all study records should be maintained by the investigator for a period of 2 years following the 
date a marketing application is approved for the drug for the indication for which it is being 
investigated; if such an application is not approved or not filed, the investigator must maintain 
a copy of all study records for 2 years after investigation is discontinued and the regulatory 
authorities are notified.  The investigator should contact ZabBio, Inc.  prior to destroying any 
required study documentation. 
9.10 Information Disclosure and Inventions  
9.10.1 Ownership  
All data and records provided by ZabBio, Inc. or generated during the study (ot her than a 
subject's medical records) and all inventions discovered in the course of conducting the study 
are the property of ZabBio, Inc.   If a written contract for the conduct of the study which 
includes ownership provisions inconsistent with this statem ent is executed, then that contract's 
ownership provisions shall apply rather than this statement.  
9.10.2 Confidentiality  
The investigator and other study site personnel will keep confidential any information provided 
by ZabBio, Inc. related to this study, including this protocol, and all data and records generated 
in the course of conducting the study, and will not use the information, data, or records for any 
purpose other than conducting the study.  These restrictions do not apply to: (1) information 
that becom es publicly available through no fault of the investigator or study site personnel; (2) 
information disclosed in confidence to an IRB/IEC solely for the evaluation of the study; (3) 
information disclosed in order to provide appropriate medical care to a st udy subject or (4) 
study results that may be published as described in the next paragraph.  If a written contract 
for the conduct of the study which includes confidentiality provisions inconsistent with this 
statement is executed, then that contract’s conf identiality provisions shall apply rather than this 
statement.  
9.10.3 Publication  
In the event the Institution and/or its employees, agents, consultants or other representatives 
(including the Principal Investigator) wish to make a publication (including any oral  disclosure 
made without obligation of confidentiality) relating to the Study or the Institution’s 
performance hereunder following completion of the Study, the Institution will deliver to 
ZabBio, Inc. a copy of the proposed written publication or an outline of such oral disclosure at 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 47 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 least thirty (30) days prior to submission for publication or presentation, as applicable.  ZabBio, 
Inc. will have the right (a) to propose modifications to the publication for protection of 
Confidential Information or other re asons, and (b) to request a delay in publication in order to 
protect patentable information.  If ZabBio, Inc. requests such a delay, the Institution will delay 
submission or presentation of the publication for a period of sixty (60) days to enable patent 
applications protecting ZabBio, Inc.’s rights in such information to be filed.  Upon the 
expiration of thirty (30) days from delivery of the proposed written publication or the outline 
of any oral disclosure, as applicable, to ZabBio, Inc., the Institution will be free to proceed 
with the written publication or the oral presentation, respectively, unless ZabBio, Inc. has 
requested the delay described above.  At least one employee of ZabBio, Inc., designated by 
ZabBio, Inc., will be considered an author on an y publication or presentation regarding the 
Study.  In no event shall the Institution publish any Confidential Information in such proposed 
publication without ZabBio, Inc. ’s prior written consent.  Notwithstanding anything to the 
contrary herein, in no event will any Interim Results (as defined below) be published, presented 
or disclosed without the prior written consent of ZabBio, Inc.  For the purposes hereof, “Interim 
Results” shall mean results from the Study prior to complete compilation of all Study data and 
review by ZabBio, Inc. and, for multicenter studies, prior to the complete set of final results of 
the Study from all centers have been published, presented or disclosed by ZabBio, Inc.  
If a written contract for the conduct of the study which inc ludes publication provisions 
inconsistent with this statement is executed, then that contract's publication provisions shall 
apply rather than this statement.  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 48 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 10 REFERENCES    
Amaral E, Perdigão A, Souza MH,  Mauck C , Waller D, Zaneveld L, Faúndes A. 
Postcoital testing after the use of a bio -adhesive acid buffering gel (ACIDFORM) and a 2% 
nonoxynol -9 product. Contraception. 2004 Dec;70(6):492- 7. 
Archer DF, Mauck CK, Viniegra -Sibal  Al, Anderson FD. Lea's Shield: a phase I postcoital 
study of a new contraceptive barrier device. Contraception 1995; 52(3):167 -73. 
Archer DF. A phase I study of Femcap used with and without spermicide. Postcoital testing. 
Contraception 1997; 56(2):111- 5. 
Barnhart K, Dart C, Culwell K. Efficacy, Safety, and Acceptability of Acidform  (Amphora) 
and Nonoxynol -9 Contraceptive Vaginal Gels [16N] Obstetrics & Gynecology: May 2016 -  
Volume 127 -  Issue -  p 118S  
Barnhart KT, Rosenberg MJ, MacKay HT, Blithe DL, Higgi ns J, Walsh T, Wan L, Thomas 
M, Creinin MD, Westhoff C, Schlaff W, Archer DF, Ayers C, Kaunitz A, Das S, Moench 
TR. Contraceptive efficacy of a novel spermicidal microbicide used with a  diaphragm: a 
randomized controlled trial. Obstet Gynecol. 2007 Sep;110(3):577- 86. 
Bronson RA. Antisperm antibodies: a critical evaluation and clinical guidelines. J Reprod 
Immunol. Dec 1999;45(2):159- 183.  
Burke AE, Barnhart K, Jensen JT, Creinin MD, Walsh TL, Wan LS, Westhoff C, Thomas  M, 
Archer D, Wu H, Liu J, Schlaff W, C arr BR, Blithe D. Contraceptive efficacy, acceptability, 
and safety of C31G and nonoxynol -9 spermicidal gels: a randomized  controlled trial. Obstet 
Gynecol. 2010 Dec;116(6):1265- 73. 
Castle PE, Whaley KJ,  Hoen TE,   Moench TR, Cone RA. Contraceptive effect o f sperm -
agglutinating monoclonal antibodies in rabbits. Biol Reprod. 1997. 
Diekman AB, Norton EJ, Westbrook VA, Klotz KL, Naaby- Hansen S,  Herr JC . Anti -sperm 
antibodies from infertile patients and their cognate sperm antigens: a review. Identity 
between SA GA-1, the H6- 3C4 antigen, and CD52. Am J Reprod Immunol. 2000 
Mar;43(3):134- 43. doi: 10.1111/j.8755- 8920.2000.430302.x. 
Hall W, S P -S, J W, JL R. Tissue Cross -Reactivity Studies for Monoclonal Antibodies: 
Predictive Value and Use for Selection of Relevant Animal Species for Toxicity Testing. In: 
JA C, ed. Preclinical Safety Evaluation of Biopharmaceuticals: A Science -Based Approach 
to Facilitating Clinical Trials.: Wiley -Interscience; 2008:208- 240. 
Isojima  S. Characterization of epitopes of seminal plasma antigen stimulating human 
monoclonal sperm -immobilizing antibodies: a personal review. Reprod Fertil Dev. 
1989;1(3):193- 201; discussion 201- 4. doi: 10.1071/rd9890193. 
Johnston DS, Goldberg E. Preclinical contr aceptive development for men and women. 
Biology of Reproduction. 2020. 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 49 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 Leach MW, Halpern WG, Johnson CW, et al. Use of tissue cross -reactivity studies in the 
development of antibody -based biopharmaceuticals: history, experience, methodology, and 
future dir ections. Toxicol Pathol. 2010;38(7):1138- 1166. 
Mauck C, Glover LH, Miller E, Allen S, Archer DF, Blumenthal P, Rosenzweig A, Dominik 
R, Sturgen K, Cooper J, Fingerhut F, Peacock L, Gabelnick HL. Lea's Shield: a  study of the 
safety and efficacy of a new vag inal barrier contraceptive used with and without spermicide 
Contraception. 1996 Jun;53(6):329- 35. 
Mauck CK, Baker JM, Barr SP, Johanson W, Archer DF. A phase I study of Femcap used 
with and without spermicide. Postcoital testing. Contraception. 1997 Aug;56(2):111- 5. 
Mauck CK, Baker JM, Barr SP, Johanson WM, Archer DF. A phase I comparative study of 
three contraceptive vaginal films containing nonoxynol -9. Postcoital testing and colposcopy. 
Contraception. 1997 Aug;56(2):97- 102.  
 
Mauck CK, Baker JM, Barr SP, Abercrombie TJ, Archer DF. A phase I comparative study of 
contraceptive vaginal films containing benzalkonium chloride and nonoxynol -
9. Postcoital testing and colposcopy. Contraception. 1997 Aug;56(2):89- 96.  
Mauck C, Callahan M, Weiner DH, Dominik R. A c omparative study of the safety and 
efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All -Flex diaphragm. 
The FemCap Investigators' Group. Contraception. 1999 Aug;60(2):71- 80. 
Mauck CK, Creinin MD, Barnhart KT, Ballagh SA, Archer DF, Ca llahan MM, Schmitz  SW, 
Bax R. A phase I comparative postcoital testing study of three concentrations of  C31G. 
Contraception. 2004 Sep;70(3):227- 31. 
Mauck CK, Brache V, Kimble T, Thurman A, Cochon L, Littlefield S, Linton K, Doncel  GF, 
Schwartz JL. A phase I randomized postcoital testing and safety study of the Caya  diaphragm  
used with 3% Nonoxynol -9 gel, ContraGel or no gel. Contraception. 2017 Aug;96(2):124-
130. 
Norton EJ, Diekman AB, Westbrook VA, et al. A male genital tract -specific carbohydrate 
epitope on human CD52: implications for immunocontraception. Tissue Antigens. 
2002;60(5):354- 364. 
Owen DH, Katz DF A  vaginal  fluid simulant. Contraception. 1999 Feb;59(2):91- 5. doi: 
10.1016/s0010- 7824(99)00010- 4. 
Politch JA, Cu- Uvin  S, Moench TR, Tashima KT, Marathe JG, Guthrie KM, Cabral H, 
Nyhuis TJ, Brennan M, Zeitlin L, Spiegel H, Mayer KH. Whaley KJ, Anderson DJ. Safety, 
acceptability and pharmacokinetics of a monoclonal antibody- based vaginal multipurpose 
prevention film (MB66): a phase 1 randomized trial. (Submitted)  
Schwartz JL, Weiner DH, Lai JJ, Frezieres RG, Creinin MD, Archer DF, Bradley L,  Barnhart  
KT, Poindexter A, Kilbourne -Brook M, Callahan MM, Mauck CK. Contraceptive efficacy, 
safety, fit, and acceptability of a  single -size diaphragm developed with end -user input. Obstet  
Gynecol. 2015 Apr;125(4):895- 903. 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 50 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 Shihata AA, Trussell J. New female intravaginal barrier contraceptive device.  Preliminary 
clinical trial. Contraception. 1991 Jul;44(1):11- 9. 
Ustay K, Behrman SJ , Tanapongpipatana S. Clinical application of antisperm -antibody test. 
Univ Mich Med Cent J. Sep- Oct 1967;33(5):225- 227. 
 
 
 
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 51 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 APPENDICES  
 
 
 
Appendix A:    Schedule of events  
Appendix B :   Table of actions according to PCT results  
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 4.0  Page 52 of 53  Version Date: 28 October -2021  
 CONFIDENTIAL  
 Appendix A . 
Schedule of Events  
PROCEDURE  
Visit 1  
Screening  
Visit 2  
Enrollment  
Visit 3  
Baseline  
(No-product) CMC  
Visit 4  
Baseline  
(No-product) PCT  
Visit 5  
24 h  safety check  
Visit 6  
Product CMC  
Visit 7  
Product PCT  
Visit 8  
24 h  safety check  
Visit 9  
No-product CMC  
Visit 10  
No-product PCT and 
Study Exit  
Informed consent  X          
Confirm eligibility  X X         
Dispense informed consent 
for male partner  X          
Enroll   X         
History  X          
Adverse Event Collection  X X X X X X X X X X 
Log concomitant medications  X X X X X X X X X X 
Condom and abstinence 
counseling  X X X X X X X X X  
Condom distribution  X    X   X   
Ovulation predictor kit 
distribution   X   X   X   
Film insertion training/review  X     X     
Film dispensed       X     
Urine pregnancy test  X ∆ ∆ ∆ ∆ X ∆ ∆ ∆ ∆ 
Urinalysis with reflex urine 
culture  X  X  X X  X   
NAATS for CT, GC, 
Trichomonas  X          
HIV blood test  X          
CBC, Metabolic Panel  X       X   
Vaginal pH  ∆  X   X  X   
Wet Prep  ∆ ∆ ∆  ∆ ∆  ∆   
Slide for Nugent scoring       X  X   
Pap ∆          
Serum for HC4 -N ELISA      X X X X X  
Serum for sperm 
agglutination      X X X X X  
Vaginal swab or aspirate for 
sperm count, HC4 -N ELISA, 
and sperm agglutination assay    
 X X X X X X X X 
Endocervical aspirate for 
Insler score, sperm count and 
motility, HC4 -N ELISA, 
sperm agglutination assay    X X X X X X X X 
CVL for immune mediators    X  X X  X X  
Vital signs  X ∆ ∆ ∆ ∆ ∆ ∆ ∆ ∆ ∆ 
Directed Physical exam  X ∆ ∆ ∆ ∆ ∆ ∆ ∆ ∆ ∆ 
Pelvic exam  X  X X X X X X X X 
Colposcopy    X X X X X X   
Woman’s acceptability 
questionnaire         X*   
Man’s acceptability 
questionnaire         X**   
X Procedure done  
∆ Procedure done if indicate d 
* Women’s questionnaire administered at this visit.   
**Men’s questionnaire administered by telephone within 72 h of intercourse , and will include questions to elicit AEs .
ZabBio, Inc.   Study Protocol  
ZB-06  ZB-06-01 
 
 
Version No.: 2.0  Page 53 of 53  Version Date: 02 -Nov-2020  
 CONFIDENTIAL  
 Appendix B . 
Table of actions according to PCT results  
Vaginal pool -  any 
sperm present  
(including 
fragments) *  Mucus -   
adequate  
(thin)  Endocervix  
Action at Baseline or Safety Cycle  Action at Test Cycle  No 
sperm  Some sperm 
but <5 
progressively 
motile  >5 
progressively 
motile  
Yes Yes    Similar results in test cycle would make 
it appear that the product was successful.  
Discontinue participant if baseline cycle.    
If this is safety cycle, may indicate 
induction of anti -sperm antibodies  Barrier successful  
Continue to next cycle.  Yes Yes    
No Yes    
Insufficient material  Yes    
Yes Yes    
 
Good PCT. Continue to next cycle if 
baseline cycle and exit participant from 
safety cycle  Barrier failed.  
Continue to safety 
cycle.  Discontinue 
participant if the result 
was clearly due to 
participant misuse of 
the product.  Yes No    
No Yes    
No No    
Insufficient material  Yes    
Insufficient material  No    
Yes No    
Poor mucus may be responsible for 
scarcity or lack of sperm in cervix. 
Repeat cycle.  Poor mucus may be 
responsible for scarcity 
or lack of sperm in 
cervix. Repeat cycle.  Yes No    
No No    
Insufficient material  No    
No Yes    
Ejaculation may not have taken place. 
Repeat cycle.  Ejaculation may not 
have taken place. 
Repeat cycle.  No No    
Insufficient material  Yes    
insufficient material  No    
*Absence of sperm in vagina means either that ejaculation did not take place or the vaginal environment is unusually hostile t o sperm, possibly due to presence of 
spermicide in test cycle.   